期刊文献+

乙烯雌酚诱发大鼠泌乳素腺瘤动物模型的建立 被引量:5

Development of a prolactin pituitary tumor model in Wistar rats induced by diethylstilbestrol
下载PDF
导出
摘要 目的建立大鼠泌乳素腺瘤动物模型,观察大鼠不同性别、用药时间和去势等因素对其发生的影响。方法将Wistar大鼠分为注射乙烯雌酚(DES)的雌性鼠试验组、去势鼠试验组和雄性鼠试验组,每组内设对照组。分别于第2,4,8和12周时观察大鼠脑垂体重量及血清泌乳素(PRL)水平和垂体组织病理学改变。结果雌性组和去势组8周时大鼠均形成腺瘤,血清PRL水平达高峰。雄性组12周时大鼠均形成腺瘤,PRL水平和垂体重量随着DES作用时间的延长而持续增高。结论腹腔注射DES可以引起Wistar大鼠泌乳素腺瘤的形成,是一种制作简便、可靠的动物模型,大鼠性别、是否去势对其形成无明显影响。 Objective To develop a prolactinoma model in Wistar rats and to investigate the influence of the gender differences, time taking of the diethylstilbestrol (DES) and ovariectomy. Methods Wistar rats were divided into DES-treated female group (F), DES-treated ovariectomized female group (O), DES-treated male group (M) and their control groups. Five rats in DES-treated and control groups were executed respectively after 2, 4, 8, and 12 weeks to investigate the weight of pituitary gland, serum prolactin (PRL) level, pituitary light microscope and immunocytochemistry. Results By 8 weeks, 100% pituitary glands of F and O developed prolactinomas, associated with increased serum PRL levels, peaked at 8 weeks. By 12 weeks, all the pituitary glands of M became prolactinomas, associated with increased serum PRL levels and the weight of pituitary gland in a time- and dose-dependent pattern. Conclusion Intraperitoneal DES injection can forming prolactinoma in Wistar rat. It is a convenient and stable pituitary tumor model. Gender difference and ovariectomy are not significantly different to forming prolactinoma.
出处 《中国微侵袭神经外科杂志》 CAS 2003年第7期318-321,共4页 Chinese Journal of Minimally Invasive Neurosurgery
关键词 乙烯雌酚 大鼠 泌乳素腺瘤 动物模型 功能性垂体肿瘤 estrogen Wistar rat prolactinoma pituitary tumor
  • 相关文献

参考文献4

  • 1[1]Nomikos P, Buchfelder M, Fahlbusch R. Current management of prolactinomas [J]. J Neurooncol, 2001; 54(2): 139-150.
  • 2[2]Spady TJ, McComb RD, Shull JD. Estrogen action in the regulation of cell proliferation, cell survival, and tumorigenesis in the rat anterior pituitary gland [J]. Endocrine, 1999; 11 (3):217-233.
  • 3[3]Heaney AP, Horwitz GA, Wang Z, et al. Early involvement of estrogen-induced pituitary tumor transforming gene and fibroblast growth factor expression in prolactinoma pathogenesis [J].Nat Med, 1999; 5(11): 1317-1321.
  • 4[4]Heaney AP, Femando M, Melmed S. Functional role of estrogen in pituitary rumor pathogenesis [J]. J Clin Invest, 2002; 109(2): 277-283.

同被引文献36

  • 1初明,胡志强,魏兰兰,张树卓,胡恩喜,董齐.白黎芦醇对垂体腺瘤GH3细胞的抑制作用[J].中华神经外科杂志,2005,21(2):105-109. 被引量:8
  • 2Jang M, Cai L, Udeani GO, et al. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science, 1997,275:218-220.
  • 3Nomikos P, Buchfelder M, Fahlbusch R. Current management of prolactinomas. J Neurooncol, 2001, 54:139-150.
  • 4Heaney AP, Fernando M, Melmed S. Functional role of estrogen in pituitary tumor pathogenesis.J Clin Invest, 2002, 109:277-283.
  • 5Mitchner NA, Garlick C, Steinmetz RW, et al. Differential regulation and action of estrogen receptors alpha and beta in GH3 cells. Endocrinology, 1999,140:2651-2658.
  • 6Lee SY, Ahn BT, Baik SH, et al. Tamoxifen inhibits GH3 cell growth in culture via enhancement of apoptosis. Neurosurgery, 1998, 43:116-123.
  • 7Lu R, Serrero G. Resveratrol, a natural product derived from grape, exhibits antiestrogenic activity and inhibits the growth of human breast cancer cells.J Cell Physiol,1999,179:297-304.
  • 8Henry LA, Witt DM. Resveratrol: phytoestrogen effects on reproductive physiology and behavior in female rats.Horm Behav, 2002,41:220-228.
  • 9Jordan VC. Antiestrogens and selective estrogen receptor modulators as multifunctional medicines. 2. clinical considerations and new agents.J Med Chem, 2003,46:1081-1111.
  • 10Molitch ME. Medical management of prolactin-secreting pituitary adenomas. Pituitary, 2002,5:55-65.

引证文献5

二级引证文献15

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部